Scisparc Ltd (SPRC) - Total Assets
Based on the latest financial reports, Scisparc Ltd (SPRC) holds total assets worth $7.62 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SPRC operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Scisparc Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Scisparc Ltd's total assets have evolved over time, based on quarterly financial data. See what is Scisparc Ltd's book value for net asset value and shareholders' equity analysis.
Scisparc Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Scisparc Ltd's total assets of $7.62 Million consist of 71.3% current assets and 28.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.2% |
| Accounts Receivable | $662.00K | 8.7% |
| Inventory | $75.00K | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.17 Million | 15.4% |
Asset Composition Trend (2006–2025)
This chart illustrates how Scisparc Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Scisparc Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scisparc Ltd's current assets represent 71.3% of total assets in 2025, a decrease from 98.3% in 2006.
- Cash Position: Cash and equivalents constituted 60.2% of total assets in 2025, up from 50.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 15.4% of total assets.
Scisparc Ltd Competitors by Total Assets
Key competitors of Scisparc Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Scisparc Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 5.36 | 11.05 |
| Quick Ratio | 2.38 | 5.28 | 11.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.18 Million | $6.10 Million | $7.58 Million |
Scisparc Ltd - Advanced Valuation Insights
This section examines the relationship between Scisparc Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -26.3% |
| Total Assets | $7.62 Million |
| Market Capitalization | $2.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scisparc Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scisparc Ltd's assets decreased by 26.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scisparc Ltd (2006–2025)
The table below shows the annual total assets of Scisparc Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.62 Million | -26.34% |
| 2024-12-31 | $10.35 Million | -7.47% |
| 2023-12-31 | $11.18 Million | +5.44% |
| 2022-12-31 | $10.61 Million | +6.95% |
| 2021-12-31 | $9.92 Million | +287.19% |
| 2020-12-31 | $2.56 Million | +121.92% |
| 2019-12-31 | $1.15 Million | -74.69% |
| 2018-12-31 | $4.56 Million | -52.33% |
| 2017-12-31 | $9.57 Million | +668.52% |
| 2016-12-31 | $1.24 Million | -25.26% |
| 2015-12-31 | $1.67 Million | +537.64% |
| 2014-12-31 | $261.18K | -84.56% |
| 2013-12-31 | $1.69 Million | +54.83% |
| 2012-12-31 | $1.09 Million | -75.33% |
| 2011-12-31 | $4.43 Million | -55.63% |
| 2010-12-31 | $9.98 Million | -18.32% |
| 2009-12-31 | $12.22 Million | +22.00% |
| 2008-12-31 | $10.01 Million | -34.18% |
| 2007-12-31 | $15.22 Million | +35.65% |
| 2006-12-31 | $11.22 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more